CMND PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

CMND ▲ +22.39% at T+5d

NEUTRAL call ✓ call won +22.39% · α vs SPY +21.31% · entry $2.59 → $3.17

Next anchor: T+20d in 9d

Last close $3.34 (close Jun 12) · +28.96% from $2.59 entry

Entry anchored
May 22, 03:59 PM ET
via Databento tick

T+1d

-4.25%

call -4.25% · α -4.26%

$2.48

settled 19d ago

T+5d

+22.39%

call +22.39% · α +21.31%

$3.17

settled 13d ago

T+20d

—

call — · α —

—

in 9d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Clearmind Medicine announced that the Johns Hopkins Medicine IRB has approved its Phase I/II trial of CMND-100 for Alcohol Use Disorder, allowing the company to proceed with Parts B and C. This is a routine clinical milestone for a micro-cap biotech with no financial data or revenue, and the stock has historically declined on similar neutral news.

Actionable Insight

This is a routine clinical milestone with no hard financial data. The stock has historically declined on similar neutral news (avg T+20 -13.33%). Monitor for actual patient enrollment data or financing updates, but no immediate catalyst for upside.

Key Facts

Johns Hopkins Medicine IRB approved Phase I/II trial of CMND-100 for Alcohol Use Disorder
Approval permits Clearmind to proceed with Parts B and C of the multicenter study
No financial terms, revenue, or guidance disclosed in the press release
Clearmind is a clinical-stage biotech with no approved products or revenue

Financial Impact

No financial figures disclosed; pre-revenue clinical-stage company

Risk Factors

No revenue or near-term commercialization path; cash burn risk
Clinical trial failure or delay could be catastrophic for a single-asset micro-cap
Historical pattern of negative stock reaction to neutral news

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3301074

33 reports for CMND

T+1T+5T+20T+60

50% Hit rate 6 of 12 directional calls best @ T+20▲ +71.18%Apr 20, 2026

Filters

Reports for CMND — sortable, filterable
	Type				Now
Jun 12, 2026 2d ago	3 NEUTRAL ★ 2/10	$3.36 awaiting T+5	awaiting T+5	—	$3.34 (−0.60%)
Jun 5, 2026 9d ago	Press Release NEUTRAL ★ 2/10	$2.76 awaiting T+5	awaiting T+5	—	$3.34 (+21.01%)
May 29, 2026 16d ago	6-K NEUTRAL ★ 3/10	$3.58 $2.91	▼ −18.72%	▼ −18.42%	$3.34 (−6.70%)
May 29, 2026 16d ago	Press Release NEUTRAL ★ 3/10	$3.58 $2.91	▼ −18.72%	▼ −18.42%	$3.34 (−6.70%)
May 26, 2026 19d ago	6-K NEUTRAL ★ 4/10	$2.59 $3.17	▲ +22.39%	▲ +21.31%	$3.34 (+28.96%)
May 26, 2026 19d ago	Press Release NEUTRAL ★ 4/10	$2.59 $3.17	▲ +22.39%	▲ +21.31%	$3.34 (+28.96%)
May 19, 2026 26d ago	6-K BEARISH ★ 6/10	$2.36 $2.58	▼ −9.28%	▼ −7.04%	$3.34 (−41.53%)
May 19, 2026 26d ago	6-K NEUTRAL ★ 4/10	$2.36 $2.58	▲ +9.28%	▲ +7.04%	$3.34 (+41.53%)
May 19, 2026 26d ago	Press Release BEARISH ★ 5/10	$2.36 $2.58	▼ −9.28%	▼ −7.04%	$3.34 (−41.53%)
May 18, 2026 27d ago	6-K BEARISH ★ 7/10	$2.36 $2.58	▼ −9.28%	▼ −7.04%	$3.34 (−41.53%)

US Market Status

Market Closed — Opens in 4h 34m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access